Success Metrics

Clinical Success Rate
90.9%

Based on 10 completed trials

Completion Rate
91%(10/11)
Active Trials
1(5%)
Results Posted
20%(2 trials)
Terminated
1(5%)

Phase Distribution

Ph phase_3
4
20%
Ph early_phase_1
1
5%
Ph phase_2
6
30%
Ph phase_4
5
25%
Ph not_applicable
4
20%

Phase Distribution

1

Early Stage

6

Mid Stage

9

Late Stage

Phase Distribution20 total trials
Early Phase 1First-in-human
1(5.0%)
Phase 2Efficacy & side effects
6(30.0%)
Phase 3Large-scale testing
4(20.0%)
Phase 4Post-market surveillance
5(25.0%)
N/ANon-phased studies
4(20.0%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

76.9%

10 of 13 finished

Non-Completion Rate

23.1%

3 ended early

Currently Active

1

trials recruiting

Total Trials

20

all time

Status Distribution
Active(2)
Completed(10)
Terminated(3)
Other(5)

Detailed Status

Completed10
unknown4
Withdrawn2
Not yet recruiting1
Suspended1
Terminated1

Development Timeline

Analytics

Development Status

Total Trials
20
Active
1
Success Rate
90.9%
Most Advanced
Phase 4

Trials by Phase

Early Phase 11 (5.0%)
Phase 26 (30.0%)
Phase 34 (20.0%)
Phase 45 (25.0%)
N/A4 (20.0%)

Trials by Status

not_yet_recruiting15%
suspended15%
terminated15%
completed1050%
unknown420%
recruiting15%
withdrawn210%

Recent Activity

Clinical Trials (20)

Showing 20 of 20 trials
NCT03525002Phase 2

Dopamine Action on Metabolism in Relation to Genotype

Completed
NCT03575000Phase 4

Bromocriptine for Patients With Schizophrenia and Prediabetes

Not Yet Recruiting
NCT05180773Phase 4

Impact of Bromocriptine on Clinical Outcomes for Peripartum Cardiomyopathy

Recruiting
NCT04128683Early Phase 1

Dopamine Receptor Contributions to Prediction Error and Reversal Learning in Anorexia Nervosa

Completed
NCT02590601Phase 3

Bromocriptine in the Treatment of Peripartum Cardiomyopathy

Withdrawn
NCT02929485Phase 4

Dopaminergic Modulation of Frontostriatal Function With a Dopamine Agonist and COMT Inhibitor

Withdrawn
NCT02544321Phase 2

Bromocriptine Quick Release (BCQR) as Adjunct Therapy in Type 1 Diabetes

Completed
NCT00998556Phase 2

Effect of Bromocriptine on Left Ventricular Function in Women With Peripartum Cardiomyopathy

Completed
NCT04351126Phase 2

Management of Ovarian Hyperstimulation Syndrome as a State of Defective Mineralocorticoid Response

Completed
NCT04038749Not Applicable

Satisfaction of Patients With the Chosen Method of Inhibition of Lactation

Unknown
NCT01673724Phase 4

Pramipexole and Bromocriptine on Nonmotor Symptoms of Early Parkinson's Disease

Completed
NCT02846493Phase 2

Efficacy and Safety of Dexamethasone Prevention for Patients of Ovarian Hyperstimulation Syndrome

Unknown
NCT02428946Not Applicable

Bromocriptine and Insulin Sensitivity

Completed
NCT02428933Not Applicable

Dopaminergic Effects on Brown Adipose Tissue

Completed
NCT02172573Phase 3

Safety and Efficacy of Pramipexole and Bromocriptine Combined With L-dopa in Parkinson's Disease

Completed
NCT02133755Phase 3

Effect of Bromocriptine on Insulin Resistance in Polycystic Ovarian Syndrome - A Pilot Study

Unknown
NCT00240409Phase 3

Randomized Single-blind Placebo Controlled Comparative Trial of Pramipexole and Bromocriptine in Parkinson's Disease

Completed
NCT01893450Not Applicable

Bromocriptine and Pentoxifylline in Ophthalmopathy Autoimmune Treatment

Terminated
NCT00004300Phase 2

Phase II Study of Stereotypes and Mental Retardation: Neurobiological Basis

Suspended
NCT00451672Phase 4

The Therapeutic Effect of Bromocriptin in Patients With Primary Aldosteronism

Unknown

All 20 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
20